| 1 |
33628103 | LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2021 |
1 |
| 2 |
34233013 | Targeting Na+ /K+ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma. | 2021 Nov |
1 |
| 3 |
34265398 | Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistance. | 2021 Nov 1 |
1 |
| 4 |
32913557 | Carnosic acid increases sorafenib-induced inhibition of ERK1/2 and STAT3 signaling which contributes to reduced cell proliferation and survival of hepatocellular carcinoma cells. | 2020 Aug 18 |
1 |
| 5 |
32970612 | GHR knockdown enhances the sensitivity of HCC cells to sorafenib. | 2020 Sep 24 |
1 |
| 6 |
30663411 | Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway. | 2019 Dec |
1 |
| 7 |
30711947 | Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib. | 2019 Feb |
2 |
| 8 |
29436591 | Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals. | 2018 May |
3 |
| 9 |
29470830 | Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1. | 2018 Jun |
1 |
| 10 |
29608984 | Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. | 2018 Jul 1 |
1 |
| 11 |
30030148 | Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. | 2018 Nov |
1 |
| 12 |
30048489 | Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. | 2018 |
1 |
| 13 |
28545562 | The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. | 2017 May 25 |
1 |
| 14 |
27863838 | Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage. | 2016 Dec |
1 |
| 15 |
25768669 | Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. | 2015 May |
1 |
| 16 |
26070816 | Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts. | 2015 Jun 13 |
1 |
| 17 |
24309512 | Multi-kinase inhibition in ovarian cancer. | 2014 Jan |
2 |
| 18 |
24573550 | BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma. | 2014 May 1 |
2 |
| 19 |
25295120 | Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity. | 2014 Nov |
2 |
| 20 |
25491250 | Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. | 2014 |
1 |
| 21 |
23467984 | Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells. | 2013 May |
4 |
| 22 |
23812726 | Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. | 2013 Dec |
1 |
| 23 |
23936348 | Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. | 2013 |
1 |
| 24 |
24649118 | Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines. | 2013 Jan |
1 |
| 25 |
22673740 | Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. | 2012 Jul |
2 |
| 26 |
22821509 | The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. | 2012 Nov |
1 |
| 27 |
21487053 | Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. | 2011 Jun |
1 |
| 28 |
21487100 | Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. | 2011 Jun 8 |
1 |
| 29 |
21691147 | Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. | 2011 Oct |
1 |
| 30 |
21790999 | Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction. | 2011 Sep |
1 |
| 31 |
19554262 | Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. | 2010 Oct |
3 |
| 32 |
20117835 | Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. | 2010 Mar |
2 |
| 33 |
20490331 | Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. | 2010 Apr 23 |
2 |
| 34 |
20502062 | Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity. | 2010 |
1 |
| 35 |
20649572 | Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. | 2010 Aug |
1 |
| 36 |
19188183 | Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. | 2009 Feb 1 |
1 |
| 37 |
19220580 | Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. | 2009 Aug |
1 |
| 38 |
20003259 | Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. | 2009 Dec 10 |
2 |
| 39 |
20038816 | Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. | 2009 Dec |
2 |
| 40 |
18593924 | Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. | 2008 Jul 1 |
2 |
| 41 |
17205056 | Antitumor activity of sorafenib in FLT3-driven leukemic cells. | 2007 Mar |
1 |
| 42 |
17341847 | Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. | 2007 |
2 |
| 43 |
17548474 | The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. | 2007 Aug |
2 |
| 44 |
17664273 | Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. | 2007 Oct 5 |
1 |
| 45 |
12503816 | ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. | 2002 Dec |
1 |